首页 > 最新文献

Hepatology最新文献

英文 中文
The impact of LRP4 mutations on hepatocellular carcinoma recurrence and immunotherapy response
IF 13.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-16 DOI: 10.1097/hep.0000000000001235
Zhen Lu, Chun-Ming Wong
{"title":"The impact of LRP4 mutations on hepatocellular carcinoma recurrence and immunotherapy response","authors":"Zhen Lu, Chun-Ming Wong","doi":"10.1097/hep.0000000000001235","DOIUrl":"https://doi.org/10.1097/hep.0000000000001235","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"17 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142986373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening
IF 13.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-16 DOI: 10.1097/hep.0000000000001181
Guneet Sidhu
{"title":"Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening","authors":"Guneet Sidhu","doi":"10.1097/hep.0000000000001181","DOIUrl":"https://doi.org/10.1097/hep.0000000000001181","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"3 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142986370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Late Breaking Abstracts
IF 13.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-16 DOI: 10.1097/hep.0000000000001193
{"title":"Late Breaking Abstracts","authors":"","doi":"10.1097/hep.0000000000001193","DOIUrl":"https://doi.org/10.1097/hep.0000000000001193","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"23 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142987589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BileMet: A new frontier in distinguishing malignant from benign biliary conditions
IF 13.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-16 DOI: 10.1097/hep.0000000000001169
Binbin Li
{"title":"BileMet: A new frontier in distinguishing malignant from benign biliary conditions","authors":"Binbin Li","doi":"10.1097/hep.0000000000001169","DOIUrl":"https://doi.org/10.1097/hep.0000000000001169","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"54 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142987605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-Invasive liver disease assessment using Blood- and Imaging-Based techniques
IF 13.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-16 DOI: 10.1097/hep.0000000000001187
{"title":"Non-Invasive liver disease assessment using Blood- and Imaging-Based techniques","authors":"","doi":"10.1097/hep.0000000000001187","DOIUrl":"https://doi.org/10.1097/hep.0000000000001187","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"4 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142987590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An unmet need in MetALD
IF 13.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-16 DOI: 10.1097/hep.0000000000001168
Kevin Harris
{"title":"An unmet need in MetALD","authors":"Kevin Harris","doi":"10.1097/hep.0000000000001168","DOIUrl":"https://doi.org/10.1097/hep.0000000000001168","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"30 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142986371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hide and Seek: Detecting HCC with novel surveillance algorithms
IF 13.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-16 DOI: 10.1097/hep.0000000000001170
John Grady, Juan Pablo Arab
{"title":"Hide and Seek: Detecting HCC with novel surveillance algorithms","authors":"John Grady, Juan Pablo Arab","doi":"10.1097/hep.0000000000001170","DOIUrl":"https://doi.org/10.1097/hep.0000000000001170","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"7 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142987585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease
IF 13.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-14 DOI: 10.1097/hep.0000000000001232
Déborah Rousseau, Stéphanie Bonnafous, Frédéric Soysouvanh, Dorian Sarrail, Manon Bourinet, Axelle Strazzulla, Stéphanie Patouraux, Arnaud Borderie, Bastien Dolfi, Alexandre Gallerand, Marwin A Farrugia, Véronique Orian-rousseau, Yingzheng Xu, Jesse W. Williams, Stoyan Ivanov, Albert Tran, Rodolphe Anty, Carmelo Luci, Philippe Gual
Background and Aims: Alcohol-related liver disease (ALD) is one of the leading causes of severe liver disease with limited pharmacological treatments for alcohol-related steatohepatitis (ASH). CD44, a glycoprotein mainly expressed in immune cells, has been implicated in multiple inflammatory diseases but has never been studied in the ALD context. We therefore studied its contribution to ASH development in mice and its expression in ALD patients Approach and Results: Here, we report that liver CD44 expression is associated with liver injury and inflammation and its deficiency (Cd44 -/-) partially protected mice upon chronic plus binge ethanol feeding (CPB-EtOH). CD44 deletion in myeloid cells (Cd44 myel-KO ) recapitulated the same protective effects associated with reduced inflammatory monocyte infiltration and neutrophil activation in the liver and diminished blood neutrophil-lymphocyte ratio (NLR). CD44-deficient neutrophils displayed reduced PMA-induced inflammatory mediator expression and increased phagocytosis of live bacteria. Cd44 myel-KO mice were also protected against hepatic steatosis mediated by CPB-EtOH or chronic ethanol feeding, due in part to increased SIRT1 mediated fatty acid beta-oxidation. CD44 neutralization with antibodies strongly decreased liver injury and inflammation (hepatic neutrophil frequency) and blood NLR upon CPB-EtOH. In samples from ALD patients, hepatic CD44 expression increased with ALD severity, correlated with hepatic TNFα and CD11b expression, and CD44-expressing neutrophils were enriched in alcohol-associated hepatitis. Conclusions: Human and experimental evidence supports CD44 as a marker of hepatic inflammation in ALD. In addition, CD44 modulates neutrophil mobilization and functions and its targeting partially prevents liver inflammation and injury in the context of acute-on-chronic alcohol drinking.
{"title":"CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease","authors":"Déborah Rousseau, Stéphanie Bonnafous, Frédéric Soysouvanh, Dorian Sarrail, Manon Bourinet, Axelle Strazzulla, Stéphanie Patouraux, Arnaud Borderie, Bastien Dolfi, Alexandre Gallerand, Marwin A Farrugia, Véronique Orian-rousseau, Yingzheng Xu, Jesse W. Williams, Stoyan Ivanov, Albert Tran, Rodolphe Anty, Carmelo Luci, Philippe Gual","doi":"10.1097/hep.0000000000001232","DOIUrl":"https://doi.org/10.1097/hep.0000000000001232","url":null,"abstract":"Background and Aims: Alcohol-related liver disease (ALD) is one of the leading causes of severe liver disease with limited pharmacological treatments for alcohol-related steatohepatitis (ASH). CD44, a glycoprotein mainly expressed in immune cells, has been implicated in multiple inflammatory diseases but has never been studied in the ALD context. We therefore studied its contribution to ASH development in mice and its expression in ALD patients Approach and Results: Here, we report that liver CD44 expression is associated with liver injury and inflammation and its deficiency (<jats:italic toggle=\"yes\">Cd44</jats:italic> <jats:sup>-/-</jats:sup>) partially protected mice upon chronic plus binge ethanol feeding (CPB-EtOH). CD44 deletion in myeloid cells (<jats:italic toggle=\"yes\">Cd44</jats:italic> <jats:sup> myel-KO </jats:sup>) recapitulated the same protective effects associated with reduced inflammatory monocyte infiltration and neutrophil activation in the liver and diminished blood neutrophil-lymphocyte ratio (NLR). CD44-deficient neutrophils displayed reduced PMA-induced inflammatory mediator expression and increased phagocytosis of live bacteria. <jats:italic toggle=\"yes\">Cd44</jats:italic> <jats:sup> myel-KO </jats:sup> mice were also protected against hepatic steatosis mediated by CPB-EtOH or chronic ethanol feeding, due in part to increased SIRT1 mediated fatty acid beta-oxidation. CD44 neutralization with antibodies strongly decreased liver injury and inflammation (hepatic neutrophil frequency) and blood NLR upon CPB-EtOH. In samples from ALD patients, hepatic CD44 expression increased with ALD severity, correlated with hepatic TNFα and CD11b expression, and CD44-expressing neutrophils were enriched in alcohol-associated hepatitis. Conclusions: Human and experimental evidence supports CD44 as a marker of hepatic inflammation in ALD. In addition, CD44 modulates neutrophil mobilization and functions and its targeting partially prevents liver inflammation and injury in the context of acute-on-chronic alcohol drinking.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"9 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142981470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multi-center prospective cohort study 肝移植前肝细胞癌的分期:一项全国性多中心前瞻性队列研究的结果
IF 13.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-14 DOI: 10.1097/hep.0000000000001231
Edison Xu, Parissa Tabrizian, Julio Gutierrez, Maarouf Hoteit, Tara Ghaziani, Kali Zhou, Neehar Parikh, Veeral Ajmera, Elizabeth Aby, Amy Shui, Rebecca Marino, Allison Martin, Christopher Wong, Karissa Kao, Shravan Dave, Sander Florman, Francis Yao, Neil Mehta
Background & Aims: Patients with hepatocellular carcinoma (HCC) meeting UNOS-downstaging (DS) criteria have excellent post-liver transplantation (LT) outcomes. Studies on HCC beyond UNOS-DS criteria (“All-comers” (AC)) have been limited by small sample size and short follow-up time, prompting this analysis. Approach & Results: 326 patients meeting UNOS-DS and 190 meeting AC criteria from 9 LT centers across 5 UNOS regions were enrolled from 2015 to 2023 and prospectively followed. Competing risk analysis and Kaplan-Meier method were used to evaluate downstaging and LT outcomes, and Fine-and-Gray and Cox models were used to identify predictors of outcomes. AC and UNOS-DS had similar median alpha-fetoprotein (15 vs. 12 ng/mL;p=0.08), MELD (9 vs. 9;p=0.52), and Child-Pugh (A vs. A;p=0.30). At 2 years from first local regional therapy, 82% of UNOS-DS and 66% of AC were successfully downstaged (p<0.001). In AC, DS rates were 72% for tumor number plus diameter of largest lesion<10, 51% for sum 10-12, and 39% for sum>12 (p=0.01). Y-90 achieved higher DS success than transarterial chemoembolization (TACE) in AC (74% vs. 65%;p<0.001). 48% of UNOS-DS and 40% of AC underwent LT (p=0.10). 5-year post-LT survival was similar between UNOS-DS and AC (74% vs. 72%;p=0.77), although 5-year post-LT recurrence was higher in AC (30% vs. 14%;p=0.02). Conclusions: Despite higher HCC recurrence and lower ITT survival in AC, post-LT survival was comparable between UNOS-DS and AC. Y-90 attained higher DS success than TACE in AC. LT after downstaging is feasible in AC, though defining an upper limit in tumor burden may be necessary.
{"title":"Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multi-center prospective cohort study","authors":"Edison Xu, Parissa Tabrizian, Julio Gutierrez, Maarouf Hoteit, Tara Ghaziani, Kali Zhou, Neehar Parikh, Veeral Ajmera, Elizabeth Aby, Amy Shui, Rebecca Marino, Allison Martin, Christopher Wong, Karissa Kao, Shravan Dave, Sander Florman, Francis Yao, Neil Mehta","doi":"10.1097/hep.0000000000001231","DOIUrl":"https://doi.org/10.1097/hep.0000000000001231","url":null,"abstract":"Background &amp; Aims: Patients with hepatocellular carcinoma (HCC) meeting UNOS-downstaging (DS) criteria have excellent post-liver transplantation (LT) outcomes. Studies on HCC beyond UNOS-DS criteria (“All-comers” (AC)) have been limited by small sample size and short follow-up time, prompting this analysis. Approach &amp; Results: 326 patients meeting UNOS-DS and 190 meeting AC criteria from 9 LT centers across 5 UNOS regions were enrolled from 2015 to 2023 and prospectively followed. Competing risk analysis and Kaplan-Meier method were used to evaluate downstaging and LT outcomes, and Fine-and-Gray and Cox models were used to identify predictors of outcomes. AC and UNOS-DS had similar median alpha-fetoprotein (15 vs. 12 ng/mL;<jats:italic toggle=\"yes\">p</jats:italic>=0.08), MELD (9 vs. 9;<jats:italic toggle=\"yes\">p</jats:italic>=0.52), and Child-Pugh (A vs. A;<jats:italic toggle=\"yes\">p</jats:italic>=0.30). At 2 years from first local regional therapy, 82% of UNOS-DS and 66% of AC were successfully downstaged (<jats:italic toggle=\"yes\">p</jats:italic>&lt;0.001). In AC, DS rates were 72% for tumor number plus diameter of largest lesion&lt;10, 51% for sum 10-12, and 39% for sum&gt;12 (<jats:italic toggle=\"yes\">p</jats:italic>=0.01). Y-90 achieved higher DS success than transarterial chemoembolization (TACE) in AC (74% vs. 65%;<jats:italic toggle=\"yes\">p</jats:italic>&lt;0.001). 48% of UNOS-DS and 40% of AC underwent LT (<jats:italic toggle=\"yes\">p</jats:italic>=0.10). 5-year post-LT survival was similar between UNOS-DS and AC (74% vs. 72%;<jats:italic toggle=\"yes\">p</jats:italic>=0.77), although 5-year post-LT recurrence was higher in AC (30% vs. 14%;<jats:italic toggle=\"yes\">p</jats:italic>=0.02). Conclusions: Despite higher HCC recurrence and lower ITT survival in AC, post-LT survival was comparable between UNOS-DS and AC. Y-90 attained higher DS success than TACE in AC. LT after downstaging is feasible in AC, though defining an upper limit in tumor burden may be necessary.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"118 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142981469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic
IF 13.5 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-14 DOI: 10.1097/hep.0000000000001227
Hiroyuki Suzuki, Naoto Fujiwara, Amit G. Singal, Thomas F. Baumert, Raymond T. Chung, Takumi Kawaguchi, Yujin Hoshida
Preventive interventions are expected to substantially improve the prognosis of patients with primary liver cancer, predominantly hepatocellular carcinoma (HCC) and cholangiocarcinoma. HCC prevention is challenging in the face of the evolving etiological landscape, particularly the sharp increase in obesity-associated metabolic disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD). Next-generation anti-HCV and HBV drugs have substantially reduced, but not eliminated, the risk of HCC and have given way to new challenges in identifying at-risk patients. The recent development of new therapeutic agents and modalities has opened unprecedented opportunities to refine primary, secondary, and tertiary HCC prevention strategies. For primary prevention (before exposure to risk factors), public health policies, such as universal HBV vaccination, have had a substantial prognostic impact. Secondary prevention (after or during active exposure to risk factors) includes regular HCC screening and chemoprevention. Emerging biomarkers and imaging modalities for HCC risk stratification and detection may enable individual risk-based personalized and cost-effective HCC screening. Clinical studies have suggested the potential utility of lipid-lowering, anti-diabetic/obesity, and anti-inflammatory agents for secondary prevention, and some of them are being evaluated in prospective clinical trials. Computational and experimental studies have identified potential chemopreventive strategies directed at diverse molecular, cellular, and systemic targets for etiology-specific and/or agnostic interventions. Tertiary prevention (in conjunction with curative-intent therapies for HCC) is an area of active research with the development of new immune-based neo/adjuvant therapies. Cholangiocarcinoma prevention may advance with recent efforts to elucidate risk factors. These advances will collectively lead to substantial improvements in liver cancer mortality rates.
{"title":"Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic","authors":"Hiroyuki Suzuki, Naoto Fujiwara, Amit G. Singal, Thomas F. Baumert, Raymond T. Chung, Takumi Kawaguchi, Yujin Hoshida","doi":"10.1097/hep.0000000000001227","DOIUrl":"https://doi.org/10.1097/hep.0000000000001227","url":null,"abstract":"Preventive interventions are expected to substantially improve the prognosis of patients with primary liver cancer, predominantly hepatocellular carcinoma (HCC) and cholangiocarcinoma. HCC prevention is challenging in the face of the evolving etiological landscape, particularly the sharp increase in obesity-associated metabolic disorders, including metabolic dysfunction-associated steatotic liver disease (MASLD). Next-generation anti-HCV and HBV drugs have substantially reduced, but not eliminated, the risk of HCC and have given way to new challenges in identifying at-risk patients. The recent development of new therapeutic agents and modalities has opened unprecedented opportunities to refine primary, secondary, and tertiary HCC prevention strategies. For primary prevention (before exposure to risk factors), public health policies, such as universal HBV vaccination, have had a substantial prognostic impact. Secondary prevention (after or during active exposure to risk factors) includes regular HCC screening and chemoprevention. Emerging biomarkers and imaging modalities for HCC risk stratification and detection may enable individual risk-based personalized and cost-effective HCC screening. Clinical studies have suggested the potential utility of lipid-lowering, anti-diabetic/obesity, and anti-inflammatory agents for secondary prevention, and some of them are being evaluated in prospective clinical trials. Computational and experimental studies have identified potential chemopreventive strategies directed at diverse molecular, cellular, and systemic targets for etiology-specific and/or agnostic interventions. Tertiary prevention (in conjunction with curative-intent therapies for HCC) is an area of active research with the development of new immune-based neo/adjuvant therapies. Cholangiocarcinoma prevention may advance with recent efforts to elucidate risk factors. These advances will collectively lead to substantial improvements in liver cancer mortality rates.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"7 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142981467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1